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Background: In Parkinson’s disease (PD), cognitive symptoms and mood changes may be 
even more distressing for the patient than motor symptoms.
Objective: Our aim was to determine the effects of bilateral subthalamic nucleus deep brain 
stimulation (STN-DBS) on working memory (WM) and mood.
Methods: Sixteen patients with PD were assessed with STN-DBS switched on (DBS-ON) and 
with dopaminergic treatment (Med-ON) compared to switched off (DBS-OFF) and without 
dopaminergic treatment (Med-OFF). The primary outcome measures were a Visual Analog 
Mood Scale (VAMS) and an emotional 2-back WM task at 12 months after DBS in the optimal 
DBS-ON/Med-ON setting compared to DBS-OFF/Med-OFF.
Results: Comparison of DBS-OFF/Med-OFF to DBS-ON/Med-ON revealed a significant 









 =79.01±17.66; P=0.001, n=16), and a trend for reduction 
in sedation (P=0.060), which was related to stimulation as shown in a subgroup of seven 
patients. The N-back task revealed a significant increase in accuracy with DBS-ON/Med-ON 
compared to DBS-OFF/Med-OFF (82.0% vs 76.0%, respectively) (P=0.044), regardless of 
stimulus valence.
Conclusion: In line with previous studies, we found that patients rated themselves subjectively 
as more alert, content, and less sedated during short-term DBS-ON. Accuracy in the WM task 
increased with the combination of DBS and medication, possibly related to higher alertness 
of the patients. Our results add to the currently mixed results described for DBS on WM and 
suggest that there are no deleterious DBS effects on this specific cognitive domain.
Keywords: deep brain stimulation, Parkinson’s disease, working memory, neuropsychiatric
Introduction
Parkinson’s disease (PD) is a disorder of basal ganglia (BG) circuit function. Cognitive 
impairments, including working memory (WM) deficits in PD, are thought to result 
from loss of ascending dopaminergic projections to prefrontal cortex (pfC) terminal 
fields, particularly those in lateral pfC.1 In PD, cognitive symptoms and mood changes 
may be even more distressing for the patient than motor symptoms.2 Subthalamic 
nucleus deep brain stimulation (STN-DBS) is an established treatment for motor com-
plications in advanced PD, which alleviates dyskinesia and improves quality of life.3 
Studies on neuropsychiatric changes after STN-DBS are still heterogeneous. There is 
evidence that, in addition to the motor loop, other cortico-BG-thalamocortical loops that 
are associated with cognitive (dorsolateral and lateral orbitofrontal loops) and emotional 
function (anterior cingular loop) may be affected by DBS by current spread, leading to 
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changes in cognition and emotion.1 The subthalamic nucleus 
is part of the hyperdirect pathway, which connects regions of 
the frontal cortex to the BG and may be critical in supporting 
integrative functions of BG-thalamo-cortical circuits through 
rapid inhibition of thalamo-cortical pathways.4 Evaluation 
of cognition and mood in STN-DBS has yielded several 
results. STN-DBS itself has been associated with decrements 
in focal neuropsychological domains, including reductions 
in WM, lexical fluency, and learning and recall efficiency.5 
However, this is not consistently reported as other studies 
report unchanged,6,7 improved or reduced memory, attention, 
and executive functions after STN-DBS8 in PD. In particu-
lar, reports on WM are mixed. Whereas some investigators 
have reported WM improvements9 together with increased 
psychomotor speed,10 others have shown either no change 
or worsening of WM.11
Two possible hypotheses currently exist. Changes in 
mood and cognition might be due to spread of current to 
adjacent pathways and regions within the STN mediating 
non-motor function,12 or they may be due to lesions along 
the trajectory for STN-DBS with the lead location near the 
head of the caudate nucleus.13 The STN-DBS lead trajec-
tory passes through the pfC, the subcortical white matter, 
the anterior limb of the internal capsule, and the BG; it was 
recently shown13 that passage of the chronic lead through 
the head of the caudate increases the risk of global cogni-
tive decline. These structures are all involved in cognitive 
or emotional functions, and the STN itself subdivides into a 
motor but also a limbic and an associative part.2 Moreover, 
patients with PD can have non-motor mood symptoms related 
to: dopaminergic deficit (ie, due to reduction in dopaminer-
gic medication after the DBS and to the progression of the 
disease and continued loss of dopaminergic projections) 
affecting the mesolimbic system (such as apathy, anxiety, 
depression, pain – hypodopaminergic syndrome) and dop-
aminergic overdose (impulse control disorders, punding – 
hyperdopaminergic syndrome).2 Deficits in verbal fluency 
and WM appear early in the disease course of PD, and are 
present in mildly depressed PD patients as well as those with 
moderate to severe depression. Previous studies suggest that 
decline in these cognitive functions varies in relationship to 
the severity of depression.14 Costa et al14 showed that patients 
with PD and major depression performed significantly worse 
than those without depression on measures of episodic and 
WM, abstract reasoning, and visuospatial abilities. PD 
patients with minor depression showed some impairment 
in these tasks, but they did not reach statistical significance. 
Moreover, neuropsychological dysfunction increases with 
increasing severity of depression in PD patients and is 
primarily linked to dysexecutive function. Furthermore, it is 
likely that a common neuropathological process involving 
the BG, limbic system, thalamus and their connections with 
the dorsolateral pfC, orbitofrontal cortex, and the anterior 
cingulate underlies both depression and executive dysfunc-
tion in PD.15 So far, there are several studies evaluating the 
effects of STN-DBS on mood. First, studies that investigated 
mood effects during STN-DBS switched on (DBS-ON) or 
switched off (DBS-OFF) in PD and studies examining mood 
before and after STN-DBS surgery, respectively. DBS-ON 
correlated with prefrontal oxygenated hemoglobin changes 
relative to DBS-OFF in a mood-eliciting near-infrared 
spectroscopy study in response to both positive and negative 
videos.16 These changes were specific to emotional stimuli 
and were not seen during neutral stimuli, and results may sug-
gest that STN stimulation influences the prefrontal cortical 
representation of positive and negative emotions.16 In a study 
by Eisenstein et al,17 PD participants with STN-DBS, who 
had been diagnosed with current mood disorders, experienced 
greater STN-DBS-induced improvement in mood. However, 
Beck Depression Inventory (BDI) and anxiety scores did 
not modulate this mood response to STN-DBS, rather the 
categorical diagnosis of mood disorders. Some studies have 
found reduced depression, apathy and psychiatric symptoms 
with DBS-ON relative to DBS-OFF. Case studies demon-
strate that some patients experience adverse changes in mood-
related behavior with STN-DBS, including fits of laughter, 
hypomania, and severe transient depression.17 A review on 
STN-DBS-induced changes in non-motor symptoms (NMS) 
in PD showed that the number and the severity of most NMS 
decrease after STN-DBS, which can have a major impact on 
patients’ quality of life.18
Our aim was to determine STN-DBS-induced short-
term changes (DBS-ON vs DBS-OFF) in emotional WM 
and mood after bilateral STN-DBS. We chose an emotional 
WM task to investigate the effect of salient stimuli on WM 
performance. We correlated symptom severity, ie, the BDI-II, 
with performance in WM.
Material and methods
subjects
We assessed 16 non-demented patients (seven women; mean 
age 61.50±7.31 [range 49–72] years; mean disease duration 
10.88±4.48 [range 3–19] years) with PD who had undergone 
STN-DBS for severe PD motor fluctuations and were treated 
with chronic DBS for at least 12 months. Demographic and 
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emotional working memory in patients with idiopathic PD after sTN-DBs
the leads (bilaterally in the STN) and the neurostimulation 
was performed as previously described.19 The DBS electrode 
used was model 3,389 (Medtronic Neurological Division) 
with four platinum-iridium cylindrical surfaces (1.27 mm 
diameter and 1.5 mm length) and a contact-to-contact separa-
tion of 0.5 mm. Contact 0 was the most caudal and contact 3 
was the most rostral. Electrode implantation was performed 
according to the standard procedures of the surgical center. 
The intended coordinates for the STN were 12 mm lateral 
from the midline, 3 mm behind the mid-commissural point, 
and 4 mm below the anterior commissure–posterior commis-
sure line. Adjustments to the intended surgical coordinates 
were made according to direct visualization of the STN on 
individual pre-operative (pre-op) stereotactic T2-weighted 
magnetic resonance imaging (MRI). Post-operative (post-op) 
MRI was performed in all patients to confirm targeting and 
suggested that at least one contact was within the STN. After 
surgery, dopamine agonists were withdrawn and levodopa 
(L-dopa) was reduced according to the improvement in 
motor state with DBS (Table 1). Written informed consent 
was obtained from the patients, and the ethics committee 
of the Charité University-Medicine in Berlin approved the 
study. In terms of psychotropic medications, one patient 
was taking clonazepam, one patient was taking citalopram 
(selective serotonin reuptake inhibitor), and one patient was 
taking antipsychotic medication (quetiapine) at the time of 
the study. No other psychotropic medications were reported. 
Other medications are shown in Table 1.
Questionnaires
Subjects were assessed on the Unified Parkinson’s Disease 
Rating Scale (UPDRS) part III motor scale, the revised 
edition BDI-II,20 and the Mattis Dementia Rating Scale 
(MDRS)21 pre-op and 12 months post-op. Depressive symp-
tom burden was defined as a BDI-II score above 17 points. 
The threshold for detecting depression can vary according 
to the type of patients.22 We set the threshold above 14 
up to 17 to detect mild clinical depression in PD patients. 
To our knowledge, a cutoff of 17 for the BDI-II has good 
sensitivity and specificity to detect clinical depression. Using 
the MDRS,21 cognitive decline was defined as an MDRS 
score ,130 (Table 1).
VaMs
The Visual Analog Mood Scale (VAMS)23 was applied to 
define short-term mood changes during each condition and 
was developed to evaluate current subjective mood state. 
We used a 16-item VAMS developed by Bond and Lader,23 
Table 1 clinical and demographical data


























1 69 F 2 1,305 360 16 141 140 13 9 11 28 4 25
2 49 M 2 610 0 6 144 144 11 3 3 29 0 39
3 55 M 2.5 700 375 16 144 133 17 5 16 36 6 33
4 62 M 2.5 1,125 890 8 138 138 9 5 12 21 10 28
5 54 M 3 1,880 553 10 142 134 7 5 13 42 4 47
6 55 M 2.5 1,575 1,000 8 144 142 2 4 20 34 14 46
7 63 M 3 1,100 720 11 144 144 11 8 14 34 12 33
8 52 M 4 875 200 15 134 144 17 16 0 42 14 38
9 72 F 2.5 653 1,278 8 na 144 17 17 10 20 19 29
10 70 F 2.5 100 0 4 144 144 4 na 26 na 14 34
11 64 F 4 1,544 460 19 144 nac 3 2 9 19 8 na
12 72 F 3 1,448 552 13 138 138 2 2 32 45 26 na
13§ 68 M 2 2,270 989.5 8 141 nac 17 # 32 56 12 na
14§ 60 F 2 573 137.5 7 142 142 7 # 20 27 18 na
15 58 F 2 829 1,370 10 142 nac 7 na 15 36 11 22.5
16 61 M 2.5 894 256 16 143 143 6 na 21 42 20 42
Notes: §Major Depressive Disorder recurrent, currently in remission (psychiatric comorbidity; lifetime), #questionnaire not sent back; &MMDr sTiM-ON, MeD-ON; 
na = not assessed, patient refused to switch off device for longer period; hY = hoehn-Yahr stage, staging ranges from 0 to 6 (most severe) at inclusion (OFF); aBDi-ii at 
inclusion; bBDi-ii at 12 months during sTiM-ON, MeD-ON. cMMse or DemTect result: (Pt 11= DemTect: 18; Pt 13= MMse: 28; Pt 15= MMse: 30); (Kinetra 10 cases; 
Activa PC 4 cases, Medtronic, St Jude 1 case, Boston Scientific 1 case); non-dopaminergic medication: Pt 1: Lantus 22 insulin Ie, s.c.; Pt 4: magnesium; Pt 5: torasemide, 
Pt 6: bisoprolol, ramipril; Pt 8: ass; Pt 9: metoprolol succinate; metformin, glibenclamide, trospium chloride, Pt 10: simvastatin, pantoprazole, metformin, ass, vitamin B, 
hydrochlorothiazide; Pt 11: pantoprazole, furosemide, Nebivolol, simvastatin, ass, ramipril; Pt 14: l-thyroxin, spironolactone, Dociton, omeprazole; Pt 15: rosuvastatin 
calcium, Nebivolol, metformin.
Abbreviations: DY, disease years; hY, hoehn-Yahr; MMse, Mini-Mental state examination; F, female; M, male; MDrs, Mattis Dementia rating scale; Bl, baseline; BDi, Beck 
Depression Inventory; UPDRS III, Unified Parkinson’s Disease Ratings Scale motor part III; Pt, patient; Med-ON, with dopaminergic treatment; Med-OFF, without dopaminergic 
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which has been used in PD patients with STN-DBS24 and to 
examine the short-term effects on mood of STN-DBS-ON 
vs DBS-OFF.25 This scale was chosen because it was easy 
for participants to understand and complete and is repeat-
able over several sessions. The VAMS covers a wide range 
of moods, including most of the basic moods, and has been 
shown to be sensitive to changes in mood state in response 
to a range of drugs that are known to affect motor perfor-
mance. It also includes somatic and alertness items, which 
may be relevant to STN-DBS. The 16 items are loaded onto 
three psychometrically-validated factors: “Alert-Sedated” 
(alert, strong, clear-headed, well-coordinated, energetic, 
quick-witted, attentive, proficient, interested), “Contented-
Discontented” (contented, tranquil, happy, amicable, gregari-
ous) and “Calm-Sedated” (calm, sedated). Each of the items 
involves a 100 mm horizontal line with word pairs on both 
sides (eg, Alert-Sedated). Patients indicate the point along 
the horizontal line that best describes how they are currently 
feeling. The score for each mood ranges from 0 to 100, with 
100 presenting a maximal level of that mood and zero repre-
senting a minimal level (or absence) of that mood.
WM task
Participants were presented an adapted version of an emo-
tional N-back paradigm (EMOBACK)26 that requires partici-
pants to decide whether the current stimulus word matches 
the one presented here and two trials earlier (2-back). This 
paradigm involves a number of key processes within WM 
and reliably engages different dorsolateral prefrontal brain 
regions within a fronto-striatal network.26 The stimuli of the 
emotional N-back task consist of emotional words related 
to the distinct emotions, like sadness and joy, and neutral 
words and were drawn from the Berlin Affective Word List.27 
So far, the EMOBACK task has not been used in patient 
populations with movement disorders. It has been validated 
in two studies. Weigand et al28 described lateralized effects 
of prefrontal repetitive transcranial magnetic stimulation 
on emotional WM in healthy participants. In a second study 
by Scheidegger et al,29 the authors investigated ketamine 
in healthy subjects and showed that ketamine modulates 
cognition-emotion interaction in the brain by inducing lateral-
ized and valence-specific effects in emotion-related cortical 
midline regions, WM-related lateral prefrontal regions and 
insula. The EMOBACK task provides a novel means of 
studying the interface between WM and emotion. Partici-
pants performed four parallel versions (respective to the four 
stimulation/medication conditions) of the EMOBACK task 
12 months after STN-DBS to exclude repetition and memory 
effects. Participants were trained prior to the start of the task. 
They were given up to three practice blocks (25 trials each) 
per condition, with feedback on their performance, until they 
demonstrated that they fully understood the task and their 
performance stabilized to a cut-off of over 50% probability in 
the N-back task. Reaction times (RTs) and accuracy measures 
were obtained for each trial. The task was programmed using 
Presentation software (Version 16.2, Neurobehavioral Sys-
tems Inc., San Francisco, CA, USA). The order of the DBS 
status was randomized and patients were assessed for each 
condition with the parallel sets of the EMOBACK task on 
different consecutive days and during the morning. Patients 
were pseudo-randomly assigned to one of four groups, to test 
the effects of DBS-ON or DBS-OFF and “with dopaminergic 
treatment” (Med-ON) or “without dopaminergic treatment” 
(Med-OFF) on VAMS and emotional WM. Half of the 
patients started with ON conditions.
experimental set-up
All subjects were assessed on the UPDRS-III motor scale. 
On the morning of the DBS-OFF/Med-OFF testing, the 
neuropsychological evaluation started 30 minutes after the 
DBS device was switched off when a stable clinical status 
was achieved. It has been shown that about 75% of motor 
change occurs within 20 minutes after change of condi-
tion.30 Longer periods were not acceptable due to study 
constraints. Last dopaminergic drug intake was at least 
12 hours before. On the day of DBS-ON/Med-ON testing, 
the neuropsychological evaluation started with a delay of 
30 minutes after the last L-dopa intake and the initial motor 
score testing. The EMOBACK task was done in front of a 
computer. Participants were seated in a comfortable chair 
in a silent room, and the monitor was placed at eye level 
90 cm from the patients. They were instructed to press, as 
quickly as possible, a button on the left of the computer’s 
keyboard if a target word was presented, and a button on the 
right side if a non-target word was presented. The duration 
of stimulus presentation was 1,000 ms, the interstimulus 
interval was 2,000 ms, and a total of 15 words, negatively 
valenced, neutral, or positively valenced were presented 
per run. In total, ten runs were presented. The words were 
presented as white uppercase letters in the center of a black 
screen. The VAMS was given to the patients after the N-back 
task was undertaken, using paper and a pen. Data on RTs of 
the EMOBACK task of three patients had to be discarded 
from the analyses in order to reduce the influence of outliers. 
Four patients had not properly filled out the VAMS and these 
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emotional working memory in patients with idiopathic PD after sTN-DBs
Statistical analysis
Questionnaires
All but the MDRS questionnaires were normally distributed 
(Shapiro-Wilk). As the number of pairs was small, we always 
compared the two most important randomized conditions, 
first the comparison DBS-ON/Med-ON vs DBS-OFF/Med-
OFF and calculated the stimulation effect (DBS-ON/Med-
OFF vs DBS-OFF/Med-OFF) if patients had participated 
in all four settings. 2×5 repeated measures (rm) ANOVA 
with two conditions (DBS-ON/Med-ON vs DBS-OFF/Med-
OFF) and five VAMS variables (contentedness, discontent, 
calmness, alertness, sedation) with Bonferroni corrections 
for alpha error accumulation due to multiple testing were 
applied. Student’s t-test and, if normalization was not given, 
non-parametric tests (Mann–Whitney U test, exact Wilcoxon 
sign rank test) were applied. Emotional 2-back WM task: 
differences in accuracy and RTs between DBS-OFF and 
DBS-ON were analyzed by means of 2×3 rmANOVAs (two 
factors: 1. “stimulation condition”: DBS-ON/Med-ON vs 
DBS-OFF/Med-OFF; 2. “valence” with three conditions, 
negative × neutral × positive) and post hoc Bonferroni 
correction. Means and standard deviations are shown in 
results. Pearson’s bivariate correlations and Spearman-Rho 
correlations between mood, cognition, and motor scores 
were calculated.
Results
At 12 months post-op, patients showed significant 
improvement in motor symptoms with STN-DBS, with 






 =16.82±9.64; Student’s t-test, T=3.884; 
P=0.004). Group mean BDI was also significantly reduced 





 =8.0±5.17; T=2.512; 
P=0.036; 30% reduction). Post-op MDRS was available in 
10/16 patients, with values that were similar to pre-op values 
(DBS-OFF mean
pre-op
 =141.3±3.52; DBS-ON/Med-OFF 
mean
post-op
 =140.1±4.22; P=0.51). None of the patients 
reported cognitive decline with DBS (Table 1).
VaMs analysis DBs-ON/Med-ON vs 
DBs-OFF/Med-OFF
We found a significant main effect for stimulation con-
dition (F
(1,11)
 =7.693; P=0.018) and VAMS variables 
(F
(4,8)
 =9.775; P=0.004) and a significant interaction effect 
between stimulation condition and VAMS variables 
(F
(4,8)
 =5.868; P=0.017) (Figure 1). Post hoc analyses 
revealed a significant increase in contentedness (%) with 





 =79.01±17.66; P=0.001, 








 =5.445; P=0.029). Furthermore, we revealed a sig-







 =6.758; P=0.016) and a tendency for 







 =3.92; P=0.060) for DBS-ON/
Med-ON vs DBS-OFF/Med-OFF. The factor calm-










In a subgroup of seven patients, a further analysis 
was done on DBS-ON/Med-OFF to disentangle the 
short-term effects of DBS and medication on mood. A 
significant stimulation effect was found for contented-





 =79.08±15.05; P=0.001, 











 =35.83±27.01; Z=-2.366; 
P=0.018, non-parametric, n=7).
emotional N-back task
Table 2 and Figure 2 show accuracy and RT for both condi-
tion and emotional valence.
Figure 1 results of the VaMs: alertness and contentedness increase during DBs 
switched on and medication.
Notes: *Significant P,0.05. **Significant P,0.01.
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emotional N-back task: accuracy
The rmANOVA for accuracy revealed a significant differ-
ence for the factor “stimulation condition” (F
(1,14)
 =4.898; 
P=0.044), with a higher overall accuracy with DBS-ON vs 
DBS-OFF (mean
on/on
: 82% vs mean
off/off
: 76%), but no signifi-
cant difference between emotional valences (F
(2,13)
 =0.319; 




emotional N-back task: rTs
Overall, response times for negatively valenced words were 
faster (mean
neg
: 813.74±48.65 ms) compared to positive 
stimuli (mean
pos
: 851.85±56.15 ms; P=0.025; 95% confi-
dence interval: -70.449, -5.769), regardless of stimulation 
condition.
emotional N-back task: rT for correct 
responses
Similarly, the rmANOVA for RT of correct responses 
revealed no main effect for the factor stimulation condition 
(DBS-ON/Med-ON vs DBS-OFF/Med-OFF) (P=0.641) 
(Table 2). A significant main effect was observed for the fac-
tor emotional valence (P=0.026), but no significant interaction 
effect between stimulation condition and valence occurred 
(P=0.128). Patients showed faster response times for negative 
stimuli (mean
neg
: 808.58±49.51 ms) than for positive stimuli, 
regardless of stimulus condition (mean
pos
: 904.42±68.04 ms).
rT for incorrect responses
The rmANOVA for RT of incorrect responses revealed no 
main effect for stimulation condition (DBS-ON/Med-ON 
Table 2 results of the emotional working memory task: mean and standard deviations N-back task
N-back task Responses Emotional stimuli Group (stimulation condition) P-value§,b
Valence DBS-ON/Med-ON DBS-OFF/Med-OFF
RT (ms) Overall 
responses
Negative 781.79±174.58 845.69±203.72 P=0.994b
Neutral 779.75±176.65 914.06±296.34 P=0.266b
Positive 814.87±190.75 888.83±237.56 P=0.095b
all§ 792.13±197.16 882.86±345.70 P=0.025*,#,§
RT (ms) correct 
responses
Negative 777.74±182.31 839.41±196.79 P=0.845b
Neutral 846.03±281.11 907.23±279.95 P=0.696b




Negative 85±12 76±17 P=0.015*,b
Neutral 80±17 77±14 P=0.508b
Positive 81±16 76±15 P=0.348b
all§ 82±12 76±16 P=0.044*,§
Notes: §aNOVa with repeated measures (factor group × rT and factor group × accuracy); bpaired t-tests between ON and OFF; *significant P,0.05; #rTs for all words 
regardless of valence; &significant main effect for the factor emotional valence.
Abbreviations: rTs, reaction times; DBs, deep brain stimulation; Med-ON, with dopaminergic treatment; Med-OFF, without dopaminergic treatment.
Figure 2 results of the eMOBacK (emotional N-back paradigm).
Notes: (A) results of the eMOBacK: accuracy during DBs switched on and medication for all emotional valenced stimuli. The repeated measures aNOVa for accuracy 
revealed a significant difference for the factor “stimulation condition” (F(1,14) =4.898; P=0.044) with a higher overall accuracy with DBs-ON vs DBs-OFF (meanon/on: 82% vs 
meanoff/off: 76%). (B) results of the eMOBacK: rTs during DBs switched on and medication for all emotional valenced stimuli. rTs for negatively valenced words were faster 
compared to positive stimuli, regardless of stimulation condition. *Significance P,0.05.
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emotional working memory in patients with idiopathic PD after sTN-DBs
vs DBS-OFF/Med-OFF) (P=0.134) and no significant 
valence effect (P=0.520) or interaction (valence × condition) 
effect (P=0.723).
Comparison between correct and false responses 
revealed a significant effect (F
(1,14)
 =29.122; P=0.000) 
with faster response times for correct responses (mean: 
811.84±59.53 ms) compared to incorrect responses (mean: 
1013.62±59.53 ms). There was no interaction effect between 




To evaluate whether improved accuracy with DBS-ON 
for the WM task was directly related to increased alertness, 
we correlated the individual change in accuracy with change 
in the VAMS alertness, contentedness, and sedation score. 
However, we failed to show a direct relationship. There 
was no significant correlation between the improvement 
in accuracy in the WM task and the change in alertness 
(Spearman-rho =-0.185; P=0.586) after 12 months follow-up 
of DBS treatment. No significant correlations were found 
between the change in the self-rating questionnaire BDI-II 
and improvement in accuracy in the WM task (Spearman-
rho =0.156; P=0.646), and no correlation between the change 
in MDRS and the improvement in accuracy (Spearman-
rho =-0.289; P=0.339). The decrease in L-dopa-equivalent 
medication did not correlate with improvement in accuracy 
in the WM task (Spearman-rho =0.364; P=0.166). Moreover, 
changes in accuracy did not significantly correlate with age 
or disease duration.
Discussion
Our main results are that WM task performance improved 
with short-term STN-DBS. Patients with DBS-ON performed 
the task with a higher overall accuracy, regardless of the 
emotional valence of the stimuli. Response times were faster 
for negative than positive stimuli, regardless of stimulation 
condition. Furthermore, PD patients who were DBS-ON/
Med-ON rated themselves subjectively as more alert and 
content compared to DBS-OFF/Med-OFF. Importantly, in 
a subgroup of patients this effect was induced by short-term 
STN-DBS alone.
It is noteworthy that PD patients without DBS treatment 
often suffer from impairments in executive functions, such as 
WM deficits, and the well-known dopamine depletion in the 
striatum probably contributes to these impairments through 
decreased connectivity between task-related brain networks.31 
On the contrary, PD patients compared to controls have 
shown a compensatory increased activation in WM-related 
brain areas (ie, pfC) to maintain behavioral performance in 
the presence of network deficits.32 Our results demonstrate 
that task performance in the WM task may be modulated 
through DBS. Importantly, and in line with previous inves-
tigations, the cognitive effects observed in patients with PD 
following STN-DBS reflect the intrinsic role of the STN in 
non-motor domains. Previous research comparing two dif-
ferent targets, involving counterbalanced “ON” vs “OFF” 
stimulation following DBS for PD suggests that neurocogni-
tive performance is slightly lower with DBS-OFF.10 Further 
large controlled studies and numerous cohort studies have 
demonstrated conflicting results on global cognitive abilities, 
attention, and memory and executive functions after STN-
DBS.7,31,33 For example, a randomized, controlled trial of 
bilateral STN and globus pallidus internus (GPi)-DBS vs best 
medical treatment found that DBS patients experienced small 
decrements on measures of WM, processing speed and visual 
delayed recall.33 Selzler et al34 examined the effects of STN-
DBS on motor disability and visual WM, with participants 
in the Med-OFF condition and DBS-ON or DBS-OFF, and 
concluded that DBS improved clinical motor function but 
had little effect on WM performance. Whereas some STN-
DBS and GPi-DBS studies have reported WM improvements 
after treatment,9,10 others have shown either no change35 or 
worsening of WM.11,36 Electrode placement is critical with 
respect to non-motor function during STN-DBS. Preventing 
stimulation of the limbic and associative parts of the STN 
might help to reduce stimulation-induced behavioral side 
effects. Moreover, the passage of the chronic lead through 
the head of the caudate nucleus can increase the risk of global 
cognitive decline.13 In our study, we demonstrated improve-
ment in accuracy and no changes in response times for WM 
during short-term DBS. On one hand, this might contradict 
an improvement in WM in PD patients due to DBS; on the 
other, it might exclude increased impulsivity due to DBS. 
Interestingly, our patients also showed higher alertness and 
contentedness during short-term DBS-ON, which could itself 
improve WM function. However, a direct relation of DBS-
induced changes could not be shown. Following STN-DBS 
positron emission tomography studies have demonstrated 
increased blood flow to dorsolateral and motor regions of pfC 
in addition to the anterior cingulate,37 which may account for 
the motor benefits but might also account for WM improve-
ment following DBS.
The impact of emotional content on WM has been exam-
ined in only a small number of studies, providing conflicting 
results. At the behavioral level in healthy subjects, negative 
stimuli were shown to have both impairing and facilitating38 
effects on WM, while an improved performance was dem-
onstrated for positive stimuli.39 Grimm et al26 showed that 
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increased activation in WM-related lateral prefrontal regions, 
whereas cognitive effort enhanced deactivation in emotion-
related cortical midline regions. Our results did not show a 
significant difference between the various emotional stimulus 
categories for PD patients after STN-DBS. The absence of 
difference between the emotional stimuli categories may be 
explained by the small sample size, ie, the lack of power of 
the statistical test.
Alertness and contentedness increased after STN-DBS. 
Subjectively perceived mood changes associated with STN-
DBS are reported in both positive and negative directions.40 
The direct effect of DBS on limbic-associative STN is 
thought to influence emotional modifications,41 ie, improve-
ment in apathy with acute stimulation, acute well-being such 
as euphoria and a decrease in sedation, mania, and impulsive 
behavior in high conflict situations or aggressive behavior.41 
The higher alertness and contentedness in our patients are 
in line with the general notion of STN stimulation-related 
increase in appetitive functioning, whereas long-term effects 
of chronic worsening of apathy have been related to reduction 
in dopamine replacement therapy.41
In contrast to a previous study,42 we did not find a correla-
tion between age or disease duration with task performance, 
possibly due to small and rather homogenous sample size.
Several limitations of this study have to be addressed. 
A limitation is that we had no age-matched healthy control 
group. Although accuracy improved significantly during 
DBS-ON compared to DBS-OFF, the study could not make 
any conclusions about the improvement resulting from a gen-
uine impairment in drug and DBS naïve patients. However, 
we compared the group against DBS-OFF/Med-OFF. In the 
same vein, due to this experimental set-up we could not 
draw conclusions upon differences between PD patients and 
controls for contentedness, discontentedness or alertness. 
Another important limitation is the fact that patients did not 
perform the emotion WM task with DBS-ON/Med-OFF. 
Therefore, we cannot show if the effect observed in this 
task was caused by the medication or electrical stimulation. 
A possible effect of the medication on this task could be a 
reduced speed due to sedation. However, we did not find 
any RT changes. A further limitation was that to improve 
precision, it would have been necessary to register electro-
myography on the finger muscle, which has been done in 
previous studies.43 Another limitation is the lack of a task 
evaluating only the finger motor speed, as control task was 
not applied. In addition, the use of self-report questionnaires, 
utilization of VAMS, and the small sample size make this 
study less representative.
In conclusion, we showed that STN-DBS can improve 
neurocognitive activity in fronto-striatal circuits, rather than 
detrimental effects. The differences in our study in neurop-
sychological outcomes of STN-DBS between conditions 
are small and they must be interpreted with caution given the 
small size of our sample. Future studies should investigate 
effects in patients under STN-DBS across different WM 
loads. However, the results of the current study are consis-
tent with results from previous studies12,17,24,42 in identifying 
cognitive and mood changes after short-term STN-DBS. The 
present work adds further evidence for improvement in NMS 
of PD patients with STN-DBS.
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